Can-Fite BioPharma Ltd. CANF
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -59.50%
- 1 year
- -81.16%
- Open
- 1.68
- Prev close
- 1.66
- Mkt cap
- 4.91M
- Vol
- 22.44K
- Avg vol
- 376.27K
- EPS
- -13.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.60
- High
- 1.70
- Forward P/E
- -2.00
- Beta
- 0.57
- Short ratio
- 1.96
- Inst. own
- 8.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.37
- 1y target
- 14.00
Key statistics
- Market cap
- 8.90M
- Enterprise value
- 2.47B
- Trailing P/E
- 0.00
- Forward P/E
- -2.00
- PEG ratio
- 0.00
- Price / sales
- 13.34
- Price / book
- 1460.00
- EPS (TTM)
- -2.60
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 667.00K
- Revenue growth
- -19.40%
- Free cash flow
- -4.55M
- Total cash
- 4.73M
- Total debt
- 57.00K
- Return on equity
- -157.62%
- Shares outstanding
- 6.10M
- Short % of float
- 2.51%
- 50-day average
- 2.08
- 200-day average
- 2.37
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 14.00
- Target (high)
- 18.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | EF Hutton | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- canfite.com
News
- Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes
- Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
- Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
- Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
- Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
- Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Your note
Sign in to keep a note on CANF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 42.17% | 650,000 | 949.00K | Sep 29, 2024 |
| Morgan Stanley | 3.29% | 50,660 | 73.96K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 1.92% | 29,570 | 43.17K | Sep 29, 2024 |
| Rhumbline Advisers | 1.10% | 16,945 | 24.74K | Sep 29, 2024 |
| Fifth Third Bancorp | 0.19% | 3,000 | 4.38K | Sep 29, 2024 |
| Wells Fargo & Company | 0.16% | 2,500 | 3.65K | Sep 29, 2024 |